Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 4 A comparison of the effects of activator protein-1 (AP-1) consensus (AP-1 cons) decoy oligodeoxynucleotide (dODN), AP-1 mutant (AP-1 mut) dODN and buffer control on neointimal area (a) and lumen area (b), expressed as the percentage of the in-stent area four weeks after percutaneous transluminal coronary angioplasty. *p < 0.05 vs. buffer control.  p < 0.05 vs. AP-1 mutant dODN.
|
